Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort StudyMario Fontán‐Vela, Lucía Fuster Sanjurjo, Eliseo Pastor et al.|Clinical Infectious Diseases|2023Cited by 39
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, Jacobo Mendioroz, Mercedes Rumayor et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 seasonOlivier Núñez, Carmen Olmedo, David Moreno‐Pérez et al.|Eurosurveillance|2025Cited by 25
Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 yearsLorena Vega-Piris, Susana Monge, José Luis Mayordomo et al.|Journal of Infection|2024Cited by 17
Nirsevimab Effectiveness Against Rsv Hospital Admission in Children Under 1 Year of Age: A Spanish Population-Based Case Control StudyOlivier Núñez, Susana Monge, Carmen Olmedo et al.|SSRN Electronic Journal|2024Cited by 4